HomeCompareBDSI vs VIG

BDSI vs VIG: Dividend Comparison 2026

BDSI yields 35.78% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BDSI wins by $151.4K in total portfolio value
10 years
BDSI
BDSI
● Live price
35.78%
Share price
$5.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$183.7K
Annual income
$28,272.37
Full BDSI calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — BDSI vs VIG

📍 BDSI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDSIVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDSI + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDSI pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDSI
Annual income on $10K today (after 15% tax)
$3,041.14/yr
After 10yr DRIP, annual income (after tax)
$24,031.51/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, BDSI beats the other by $23,879.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDSI + VIG for your $10,000?

BDSI: 50%VIG: 50%
100% VIG50/50100% BDSI
Portfolio after 10yr
$108.0K
Annual income
$14,225.76/yr
Blended yield
13.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BDSI right now

BDSI
Analyst Ratings
9
Buy
2
Hold
Consensus: Buy
Altman Z
2.8
Piotroski
6/9
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDSI buys
0
VIG buys
0
No recent congressional trades found for BDSI or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDSIVIG
Forward yield35.78%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$183.7K$32.4K
Annual income after 10y$28,272.37$179.15
Total dividends collected$133.5K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BDSI vs VIG ($10,000, DRIP)

YearBDSI PortfolioBDSI Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$14,278$3,577.82$11,304$163.92+$3.0KBDSI
2$20,051$4,774.15$12,759$166.33+$7.3KBDSI
3$27,721$6,266.08$14,382$168.52+$13.3KBDSI
4$37,758$8,096.12$16,192$170.52+$21.6KBDSI
5$50,707$10,305.96$18,210$172.34+$32.5KBDSI
6$67,191$12,934.95$20,460$173.98+$46.7KBDSI
7$87,913$16,018.70$22,968$175.48+$64.9KBDSI
8$113,655$19,587.81$25,763$176.83+$87.9KBDSI
9$145,277$23,666.62$28,878$178.05+$116.4KBDSI
10$183,719$28,272.37$32,350$179.15+$151.4KBDSI

BDSI vs VIG: Complete Analysis 2026

BDSIStock

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Full BDSI Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this BDSI vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDSI vs SCHDBDSI vs JEPIBDSI vs OBDSI vs KOBDSI vs MAINBDSI vs DGROBDSI vs NOBLBDSI vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.